The health benefits of vaccination for HPV are well accepted, but knowledge is lacking on why children have not received their vaccination. We found this by examining factors contributing to not receiving the vaccine. This information will inform the design of effective and cost-effective interventions to increase HPV vaccination rates worldwide.
The use of HPV vaccine decreases the high rates of cervical cancer. This treatment is highly effective in adolescents and young adult women aged 13 to 24 years. There are no vaccine contraindications, and there are no adverse effects after the HPV vaccination. HPV vaccination is administered safely and is effective for those ages 13 to 24 years.
For HPV-positive adolescents, sexual contact and non-vaccination related signs were common. For HPV-negative adolescents, vaccination-related signs were more common. Screened children should be counseled regarding possible health complaints that may occur in the short term.
A substantial proportion of adolescents do not receive HPV vaccinations. Most adolescents who do not get HPV vaccinations have never been to the dentist and have not received an update on their vaccination status during any clinical visit.
Vaccine-induced IgG antibody formation appears to be an important factor determinant of the persistence of anti-Vp125 antibodies for a long period of time in patients vaccinated with the vaccine.
Therapeutic reminders are feasible, cost-effective, and have a small effect on clinical activity. The text message approach should be evaluated in a larger study of a more diverse patient population.
In the Netherlands, HPV vaccination seems to be as safe as in other Western countries. There is currently very limited evidence for an association with increased risk of anal cancer. There may also be a decrease in the risk of cervical cancer, but this needs confirmation.
While HPV vaccine does not appear to run in families, these findings raise the possibility of an interaction between vaccine variables and host factors, such as genetic susceptibility. Further family-based analysis is warranted.
In a recent study, findings of this study provide an accurate description of common text message side effects and will help clinicians to more effectively assess and treat the patients with text message, not only the vaccination for HPV, but also to other possible side effects of mHealth.
The authors of 2 recent systematic review articles identified patients who should consider clinical trials to support their decision to receive HPV vaccine. Further research to identify and characterize these patients is needed to develop more effective approaches to support individuals making their treatment decisions.
Data from a recent study population, the average age of participants was 40.8 years. Data from a recent study suggest that younger women have a higher rate of [cervical cancer](https://www.withpower.com/clinical-trials/cervical-cancer) incidence from cervical cancer-related human papillomavirus infection and that younger men may have a higher risk of developing penile cancer as a result of human papillomavirus-induced sexual promiscuity.